Alnylam Announces Positive Phase II Data for Patisiranfor for Treatment of TTR-Mediated Amyloidosis, Initiates Phase III Trial
November 10, 2013 at 09:26 AM EST
Alnylam Pharmaceuticals, (NASDAQ: ALNY ), a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase II trial of patisiran (ALN-TTR02), an RNAi
